Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market
Source: Streetwise Reports  (7/2/26)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains. More >

Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity
Source: Streetwise Reports  (7/2/26)
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors. More >

Satellos Bioscience Fast Track Win Fuels DMD Hopes
Source: Streetwise Reports  (7/2/26)
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now. More >

Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings
Source: Streetwise Reports  (7/1/26)
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial. More >

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1
Source: Streetwise Reports  (6/27/26)
Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors. More >

uniQure Epilepsy Gene Therapy Data Draws Investor Focus
Source: Streetwise Reports  (6/26/26)
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next. More >

A New Obesity Drug Just Reached Human Trials. Here's What Comes Next
Source: Streetwise Reports  (6/26/26)
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application. More >

Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment, Gets Buy Rating
Source: Streetwise Reports  (6/25/26)
uniQure N.V. (QURE:NASDAQ) announced initial six-month data for AMT-260 treating refractory epilepsy, with three of six patients showing 79-100% seizure reduction. More >

San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach
Source: Dr. Joseph Pantginis  (6/25/26)
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts. More >

Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth
Source: Streetwise Reports  (6/20/26)
Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities. More >

Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand
Source: Streetwise Reports  (6/20/26)
Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors. More >

Sernova Biotherapeutics Advances Toward Diabetes Solutions with FDA Orphan Drug Designation and Strengthened Capital Base
Source: Streetwise Reports  (6/19/26)
Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors. More >

Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program
Source: Streetwise Reports  (6/19/26)
Traws Pharma, Inc.'s (TRAW:NASDAQ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral. More >

Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data
Source: Streetwise Reports  (6/19/26)
Rezolute Inc. (RZLT:NASDAQ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026. More >

Biotech Secures Major FDA Orphan Drug Designation for Diabetes Treatment
Source: Streetwise Reports  (6/18/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) announces it has been granted orphan drug designation for autologous islet transplantation (AIT) for preventing diabetes following a total pancreatectomy. More >

enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape
Source: Streetwise Reports  (6/18/26)
Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors. More >

Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition
Source: Streetwise Reports  (6/17/26)
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors. More >

Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA
Source: Streetwise Reports  (6/17/26)
enGene Therapeutics Inc. (ENGN:NASDAQ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock. More >

A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience
Source: Streetwise Reports  (6/16/26)
Apotex Health Corp. (APTX:TSX) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) reported new AUSTEDO data and added a late-stage Tourette syndrome asset. More >

Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies
Source: Streetwise Reports  (6/16/26)
Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider. More >

Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal
Source: Streetwise Reports  (6/15/26)
Analysts downgrade Nuvalent Inc (NUVL:NASDAQ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely. More >

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment
Source: Streetwise Reports  (6/13/26)
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market. More >

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors
Source: Streetwise Reports  (6/12/26)
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets. More >

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results
Source: Streetwise Reports  (6/12/26)
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients. More >

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity
Source: Streetwise Reports  (6/10/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market. More >